Pharmaceutical NanotechnologyIn vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery☆
Section snippets
The note
The monodisperse, multivalent and globular nature of dendrimers has led many groups to consider their use as vehicles for drug delivery (Cloninger, 2002, Esfand and Tomalia, 2001, Patri et al., 2002, Aulenta et al., 2003). This use requires these architectures to display low toxicity and be biocompatible, nonimmunogenic, and biodegradable or subject to ready clearance. These studies address the acute and subchronic toxicity of molecule 1, a third generation, cationic dendrimer based on melamine
Acknowledgements
The National Institutes of Health (GM 64650) and the Center for Microencapsulation and Drug Delivery at Texas A&M University supported these investigations.
References (14)
- et al.
Dendrimers: a new class of nanoscopic containers and delivery devices
Eur. Polym. J
(2003) - et al.
A PEGylated dendritic nanoparticulate carrier of fluorouracil
Int. J. Pharm
(2003) Biological applications of dendrimers
Curr. Opin. Chem. Biol
(2002)- et al.
Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers
J. Controlled Release
(2002) - et al.
Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
Drug Discov. Today
(2001) - et al.
In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis
Biomaterials
(2003) - et al.
The influence of surface modification on the cytotoxicity of PAMAM dendrimers
Int. J. Pharm
(2003)
Cited by (0)
- ☆
Supplementary data associated with this article can be found at doi: 10.1016/j.ijpharm.2004.04.023.
- 1
Co-corresponding author. Tel.: +1-979-458-1538; fax: +1-979-845-0699.